Design, synthesis, and biological evaluation of new 5-ht4 receptor agonists: Application as amyloid cascade modulators and potential therapeutic utility in alzheimer's disease

Journal of Medicinal Chemistry

Volumn 52, Issue 8, 2009, Pages 2214-2225

  Russo, Olivier ^a,d   Cachard Chastel, Marthe ^c,d   Riviere, Celine ^e   Giner, Mireille ^a,d   Soulier, J L ^a,d   Berthouze, Magali ^b,d   Richard, Tristan ^e   Monti, J P ^e   Sicsic, Sames ^a,d   Lezoualc'h, Frank ^b,d   Berque Bestel, Isabelle ^f  

^a CNRS   (France)

^b Universite Paris Sud   (France)

^c University of Paris XI   (France)

^d IPSIT   (France)

^e Bordeaux Segalen University   (France)

^f INSERM U869   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [[6 [6 AMINO 1,3 DIOXO 1H BENZO[DE]ISOQUINOLIN 2(3H) YL]HEXANOYL]AMINO]PIPERIDINO]ETHYL 4 AMINO 5 CHLORO 2 METHOXYBENZOATE; 4 AMINO 5 CHLORO 2 METHOXYBENZOIC ACID 2 (1 PIPERIDINYL)ETHYL ESTER; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; SEROTONIN 4 AGONIST; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN CORTEX; BRAIN LEVEL; COGNITIVE DEFECT; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PHARMACOPHORE; PROTEIN POLYMERIZATION; PROTEIN SYNTHESIS; RAT; RECEPTOR AFFINITY; SOLID PHASE SYNTHESIS; TECHNIQUE;

ALZHEIMER DISEASE; AMINOBENZOIC ACIDS; AMYLOID; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BIOPOLYMERS; CELL LINE, TUMOR; CEREBRAL CORTEX; CYCLIC AMP; DRUG DESIGN; HIPPOCAMPUS; HUMANS; MALE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PIPERIDINES; RADIOLIGAND ASSAY; RATS; SEROTONIN 5-HT4 RECEPTOR AGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 65449154371     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801327q     Document Type: Article

References (35)

1. (4) Receptor Ligands: Applications and New Prospects. J. Med. Chem. 2003, 46, 319-344.
2. Bockaert, J.; Claeysen, S.; Compan, V.; Dumuis, A. 5-HT4 receptors: History, molecular pharmacology and brain functions. Neuropharmacoloev 2008, 55, 922-931.
3. De Maeyer, J. H.; Lefebvre, R. A.; Schuurkes, J. A. J. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol. Motil. 2008, 20, 99-112.
4. (4))) receptor agonists are putative antidepressants with a rapid onset of action. Neuron. 2007, 55, 679- 681.
5. 4 receptors is mediated by increases in CART in the nucleus accumbens. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 16335-16340.
6. Lezoualc'h, F. 5-HT4 receptor and Alzheimer's disease: the amyloid connection. Exp. Neurol. 2007, 205, 325-329.
7. Cho, S.; Hu, Y. Activation of 5-HT4 receptors inhibits secretion of beta-amyloid peptides and increases neuronal survival. Exp. Neurol. 2007, 203, 274-278.
8. 4receptor regulates secretion of non-amyloidogenic precursor protein. J. Biol. Chem. 2001, 276, 44881-44888.
9. 4 receptors: a novel therapeutic target for Alzheimer's disease. Curr Alzheimet Res. 2004, 79-86.
10. Moser, P. C.;, E.; Bergis, O.; Jegham, S.; Lochead, A.; Duconseille, E.; Terranova, J.-P.; Caille, D.; Berque-Bestel, I.; Lezoualc'h, F.; Fischmeister, R.; Dumuis, A.; Bockaert, J.; George, P.; Soubrie, P.; Scatton, B. SL65.0155, a novel 5-hydroxytryptamine4 receptor partial agonist with potent cognition-enhancing properties. J. Pharmacol. Ezo Ther. 2002, 302, 731-742.
11. Mohler, E. G.; Shacham, S.; Noiman, S.; Lezoualc'h, F.; Robert, S.; Gastineau, M.; Rutkowski, J.; Marantz, Y.; Dumuis, A.; Bockaert, J.; Gold, P. E.; Ragozzino, M. E. VRX-03011, a novel 5-HT4 agonist, enhances memory and hippocampal acetylcholine efflux. Neuropharmacoloev 2007, 53, 563-573.
12. Yang, D.; Soulier, J. L.; Sicsic, S.; Mathe-Allainmat, M.; Bremont, B.; Croci, T.; Cardamone, R.; Aureggi, G.; Langlois, M. New esters of 4-amino-5-chloro-2-methoxybenzoic acid as potent agonists and antagonists for 5-HT4 receptors. J. Med. Chem. 1997, 40, 608-621.
13. 4 receptor agonists increase sAPPalpha levels in the cortex and hippocampus of male C57BL/6j mice. Br. J. Pharmacol. 2007, 150, 883-892.
14. 4-R D100 (3.32) A) Generates a Gs-coupled Receptor Activated Exclusively by Synthetic Ligands (RASSL). J. Biol. Chem. 2003, 278, 699-702.
15. 4 receptor. PLoS One 2007, 2, e1317.
16. 4R.
17. Berque-Bestel, I.; Lezoualc'h, F.; Jockers, R. Bivalent ligands as specific pharmacological tools for G protein-coupled receptor dimers. Curr. Drug. DiscoVery Technol. 2008, 5, 312-8.
18. 4 Receptor Oligomers. Curr. Pharm. Des. 2009, 15, 719-729.
19. Liu, Z.; Zhang, J.; Zhang, A. Design of Multivalent Ligand Targeting G-Protein-Coupled Receptors. Curr. Pharm. Des. 2009, 15, 682-718.
20. 4) receptor antagonists on constitutively active wild-type and mutated receptors. Mol. Pharmacol. 2000, 58 (1), 136-144.
21. (4) receptor by site-directed mutagenesis and molecular modeling. Br. J. Pharmacol 2000, 130, 527-538.
22. 4 receptor binding site: exploration of a hydrophobic pocket. Br. J. Pharmacol 2004, 143, 361-370.
23. Fukuyama, T.; Jow, C.-K.; Cheung, M. 2- and 4-Nitrobenzenesulfonamides: Exceptionally versatile means for preparation of secondary amines and protection of amines. Tetrahedron Leet. 1995, 36, 6373- 6374.
24. Prugh, J. D.; Birchenough, L. A.; Egbertson, M. S. A simple method of protecting a secondary amine with tert-butyloxycarbonyl (BOC) in the presence of a primary amine. Synth. Commun. 1992, 22, 2357- 2360.
25. Gisin, B. F. The Monitoring of Reactions in Solid-Phase Peptide Synthesis with Picric Acid. Anal. Chim. Acta 1972, 58, 248-249.
26. Berque-Bestel, I.; Soulier, J. L.; Giner, M.; Rivail, L.; Langlois, M.; Sicsic, S. Synthesis and characterization of the first fluorescent antagonists for human 5-HT4 receptors. J. Med. Chem. 2003, 46, 2606- 2620.
27. Dubey, K. K.; Singh, R. K.; Msra, K. A novel fluorescent tag for labelling of some antisense oligonucleotides. Neurochetm. Int 1997, 31, 405-412.
28. (4) receptor dimers. J. Med. Chem. 2007, 50, 4482-4492.
29. 4(e)) receptor from human heart and comparative analysis of its pharmacological profile in C6-glial and CHO cell lines. Br. J Pharmacol. 2000, 129, 771-781.
30. Riviere, C.; Richard, T.; Quentin, L.; Krisa, S.; Merillon, J. M.; Monti, J. P. Inhibitory activity of stilbenes on Alzheimer's beta-amyloid fibrils in vitro. Bioorg. Med. Chem. 2007, 15, 1160-1167.
31. Klegeris, A.; Walker, D. G.; McGeer, P. L. Activation of macrophages by Alzheimer beta amyloid peptide. Biochem. Biophys. Res. Commun. 1994, 199, 984-991.
32. Pike, C. J.; Walencewicz-Wasserman, A. J.; Kosmoski, J.; Cribbs, D. H.; Glabe, C. G.; Cotman, C. W. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J. Neurochem. 1995, 64, 253-265.
33. Ono, K.; Hasegawa, K.; Naiki, H.; Yamada, M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J. Neurosci. Res. 2004, 75, 742-750.
34. Yang, F.; Lim, G. P.; Begum, A. N.; Ubeda, O. J.; Simmons, M. R.; Ambegaokar, S. S.; Chen, P. P.; Kayed, R.; Glabe, C. G.; Frautschy, S. A.; Cole, G. M. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 2005, 280, 5892-5901.
35. Riviere, C; Richard, T.; Vitrac, X.; Mérillon, J. M.; Valls, J.; Monti, J. P. New polyphenols active on beta-amyloid aggregation. Bioorg. Med. Chem. Lett. 2008, 18, 828-831. JM801327Q